`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`COALITION FOR AFFORDABLE DRUGS VIII, LLC
`
`Petitioner
`
`v.
`
`THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
`
`Patent Owner
`
`Case No. IPR2015-01836
`
`Patent No. 7,932,268
`
`PATENT OWNER’S MOTION TO SEAL
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Pursuant to 37 C.F.R. §§ 42.14, 42.54, Patent Owner The Trustees of the
`
`University of Pennsylvania (“Patent Owner”) respectfully moves to seal portions
`
`of Exhibits 2057, 2081, and 2082, filed herewith, which contain confidential
`
`business information of Patent Owner and/or confidential patient information. In
`
`support of this Motion, Patent Owner is also submitting an unopposed motion for
`
`entry of the Board’s default protective order. See 37 C.F.R. § 42.54(a).
`
`I.
`
`GOOD CAUSE EXISTS FOR SEALING CERTAIN CONFIDENTIAL
`INFORMATION
`
`In determining whether to grant a Motion to Seal, the Board must find “good
`
`cause” and “strike a balance between the public’s interest in maintaining a
`
`complete and understandable file history and the parties’ interest in protecting truly
`
`sensitive information.” 37 C.F.R. § 42.54(a); 77 Fed. Reg. 48756, 48760 (Aug. 14,
`
`2012). As described in the Office Trial Practice Guide, the Board identifies
`
`confidential information in a manner “consistent with Federal Rule of Civil
`
`Procedure 26(c)(1)(G), which provides for protective orders for trade secret or
`
`other confidential research, development, or commercial information.” 77 Fed.
`
`Reg. 48756, 48760 (Aug. 14, 2012).
`
`Exhibit 2082 contains confidential patient information. This exhibit
`
`references specific clinical data for patients in connection with studies conducted
`
`by or through the University of Pennsylvania. Patent Owner is obligated to
`
`maintain the foregoing data as confidential. The public’s interest in accessing this
`
`
`
`1
`
`
`
`
`
`information for the purposes of the patentability of the challenged claims in this
`
`proceeding is outweighed by the prejudicial effect that such disclosure would have
`
`on Patent Owner, who is required to maintain the privacy of patients treated by or
`
`through the University of Pennsylvania.
`
`Exhibits 2057 and 2081 contain confidential business information of Patent
`
`Owner (and of Aegerion, Inc., the exclusive licensee of the patent under review in
`
`this proceeding) relating to certain clinical trials conducted on lomitapide by Patent
`
`Owner or by Bristol-Myers Squibb Company (“BMS”). Exhibit 2057 contains
`
`detailed information regarding the methodology of and summary results from a
`
`clinical study conducted by BMS on lomitapide that is non-public and proprietary
`
`to Patent Owner. Exhibit 2081 contains business confidential information largely
`
`about projects unrelated to the subject matter claimed in the patent at issue in this
`
`IPR, that is also proprietary to Patent Owner. Patent Owner has an interest in
`
`keeping this business information confidential because it is sensitive, competitive
`
`business information. Again, the public’s interest in accessing this information for
`
`the purposes of the patentability of the challenged claims in this proceeding is
`
`outweighed by the Patent Owner’s interest in maintaining confidential, proprietary
`
`business information.
`
`Further, in conjunction with this motion, Patent Owner is submitting non-
`
`confidential, redacted versions of Exhibits 2057 and 2081-2082. The proprietary
`
`
`
`
`2
`
`
`
`
`
`data and information contained in Exhibits 2057 and 2081-2082 is not essential to
`
`an understanding of the accompanying Patent Owner Response and related
`
`exhibits. Indeed, the only information not reflected in the redacted versions of
`
`these exhibits is the data described above, to wit, the precise clinical patient data or
`
`confidential business information proprietary to the Patent Owner or BMS. And as
`
`noted above, in the case of Exhibit 2081, the redacted information is largely
`
`irrelevant to the present proceedings. In contrast, the public disclosure of this
`
`information requires the Patent Owner to disclose proprietary, confidential
`
`information. Accordingly, good cause exists to seal the confidential patient data
`
`and business confidential information contained in Exhibits 2057 and 2081-2082.
`
`Finally, to the extent the Board chooses to unseal these documents (e.g., it
`
`substantively relies on them in its final written decision), Patent Owner requests
`
`the opportunity to redact those portions of these exhibits on which the Board does
`
`not rely.
`
`For the foregoing reasons, the Board should seal the unredacted versions of
`
`Exhibits 2057 and 2081-2082.
`
`II.
`
`CERTIFICATION OF NON-PUBLICATION
`
`To the undersigned counsel’s knowledge, the information sought to be
`
`sealed by this motion has not been published or otherwise made public.
`
`
`
`
`
`
`3
`
`
`
`
`
`III. CERTIFICATION OF CONFERENCE WITH OPPOSING PARTY
`PURSUANT TO 37 C.F.R. § 42.54.
`
`Patent Owner has conferred with Petitioner, and Petitioner takes no position
`
`on this motion until it has had an opportunity to review it.
`
`
`
`THEREFORE, Patent Owner respectfully requests that the Board grant
`
`Patent Owner’s Motion to Seal.
`
`Respectfully submitted,
`
`/William G. James/
`William G. James
`Registration No. 55,931
`GOODWIN PROCTER LLP
`901 New York Ave. NW
`Washington, DC 20001
`Tel: 202.346-4000
`Fax: 202-346-4444
`
`Dated: June 7, 2016
`
`
`
`
`4
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`The undersigned hereby certifies that a copy of the foregoing PATENT
`
`OWNER’S MOTION TO SEAL was served electronically via e-mail on June 7,
`
`2016 on the following:
`
`
`
`
`
`/Russell Warnick/
`Russell Warnick
`
`
`
`Dr. Gregory Gonsalves
`2216 Beacon Lane
`Falls Church, Virginia 22043
`(571) 419-7252
`gonsalves@gonsalveslawfirm.com
`
`Christopher Casieri
`McNeely, Hare & War LLP
`12 Roszel Road, Suite C104
`Princeton, NJ 08540
`(609) 731-3668
`chris@miplaw.com
`
`
`
`Counsel for Petitioner Coalition
`for Affordable Drugs VIII, LLC
`
`
`
`Dated:
`
`June 7, 2016